|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Elan Pharmaceuticals |
| Information provided by: | Elan Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00076544 |
Purpose
The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.
| Condition | Intervention | Phase |
|
Pain |
Drug: Ziconotide |
Phase III |
| Drug Information available for: | SNX 111 |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Safety Study |
| Official Title: | An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 65 Study Locations |
| Elan Pharmaceuticals |
More Information
| Study ID Numbers: | ELN92045-501 |
| First Received: | January 26, 2004 |
| Last Updated: | February 2, 2007 |
| ClinicalTrials.gov Identifier: | NCT00076544 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|